Deucravacitinib (Sotyktu) for Plaque Psoriasis
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1670b ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Psoriasis.
Abstract (Originalsprache)
The FDA has approved deucravacitinib (Sotyktu – BMS), an oral tyrosine kinase 2 (TYK2) inhibitor, for once-daily treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Deucravacitinib is the first selective TYK2 inhibitor to be approved in the US for any indication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2023). Deucravacitinib (Sotyktu) for Plaque Psoriasis. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1670b
Vancouver
Deucravacitinib (Sotyktu) for Plaque Psoriasis. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1670b
BibTeX
@article{euvimed2023,
title = {Deucravacitinib (Sotyktu) for Plaque Psoriasis},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1670b}
}
EUVIMED